EC approves Roche's Polivy combo in patients with previously treated aggressive lymphoma Medical Dialogues Bureau22 Jan 2020 11:01 AM ISTRoche announced that the European Commission has granted conditional marketing authorisation for Polivy® (polatuzumab vedotin), in combination with...
BeiGene gets USFDA approval for lymphoma drug Brukinsa Medical Dialogues Bureau17 Nov 2019 9:20 AM ISTBeiGene tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies. About three-quarters were Asian, 21%...
CDSCO committee tells Roche to submit Phase III clinical trial data of blood cancer combo drug Farhat Nasim27 Oct 2019 11:30 AM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO), recently recommended drugmaker,...
Novartis, Gilead costly cancer therapies Yescarta, Kymriah losing patients to experimental treatments Medical Dialogues Bureau3 Aug 2019 9:15 AM ISTBoth Gilead's Yescarta and Novartis's Kymriah - which are part of a class of therapies known in the medical field as "CAR-T" - were approved in 2017....
Pfizer gets USFDA nod for biosimilar to Rituximab Medical Dialogues Bureau25 July 2019 8:59 AM ISTRuxience is a mAb biosimilar to Rituxan which works by targeting a protein called CD20, which is present on the surface of B cells. Ruxience is...
Unichem Labs gets USFDA nod to market Allopurinol tablets Farhat Nasim15 March 2019 9:35 AM ISTAllopurinol tablets will be commercialised from company's Ghaziabad plant, Unichem Laboratories said.New Delhi: Drug firm Unichem Laboratories...
Novartis Kymriah wins UK backing after initial lymphoma snub Medical Dialogues Bureau3 Feb 2019 10:00 AM IST"Today's positive announcement regarding access to Kymriah treatment in England and Wales was secured as a result of our close working collaboration...
Gilead Sciences new drug keeps 56 percent of lymphoma trial patients alive Ruby Khatun Khatun11 Dec 2017 10:30 AM ISTMore than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a...
